

Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination (ECVM)

First published: 01/04/2021

Last updated: 01/07/2024

Study

Finalised

Administrative details

EU PAS number

EUPAS40404

Study ID

50430

DARWIN EU® study

No

Study countries

 Italy

 Netherlands

 Spain

Study description

This study will monitor AESI prior and following COVID-19 vaccination, with the purpose to estimate the incidence rates and pick up signals. This study will be conducted with funding from the EMA and in 4 data sources that have access to COVID-19 vaccine data and are able to rapidly update their data


Study status

Finalised

Research institutions and networks

Institutions

University Medical Center Utrecht (UMCU)

 Netherlands

First published: 24/11/2021

Last updated: 22/02/2024


Institution

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

Division of Pharmacoepidemiology & Clinical Pharmacology (PECP), Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University

 Netherlands

First published: 01/03/2010


Last updated: 23/05/2024

Institution

Educational Institution

ENCePP partner

University Medical Center Utrecht (UMCU)

 Netherlands

First published: 24/11/2021

Last updated: 22/02/2024


Institution

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

 Netherlands

First published: 07/01/2022

Last updated: 19/12/2025

Institution

Non-Pharmaceutical company

ENCePP partner

Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

 Spain

First published: 01/02/2024

Last updated: 04/09/2024

Institution

EU Institution/Body/Agency

Not-for-profit


Regulatory Authority


ENCePP partner


Multiple centres: 6 centres are involved in the study


Networks


Vaccine monitoring Collaboration for Europe (VAC4EU)

 Belgium


 Denmark


 Finland

 France


 Germany

 Italy

 Netherlands

 Norway

 Spain

 United Kingdom

First published: 22/09/2020


Last updated: 22/09/2020

Network

Outdated

ENCePP partner

EU Pharmacoepidemiology and Pharmacovigilance (PE&PV) Research Network

 Netherlands

First published: 01/02/2024

Last updated: 24/09/2025

Network

Contact details

Study institution contact

Miriam Sturkenboom m.c.j.sturkenboom@umcutrecht.nl

Study contact

m.c.j.sturkenboom@umcutrecht.nl

Primary lead investigator

Miriam Sturkenboom

Study timelines

Date when funding contract was signed

Actual: 15/12/2020

Study start date

Planned: 15/02/2021

Actual: 15/02/2021

Data analysis start date

Planned: 30/03/2021

Date of final study report

Planned: 30/11/2021

Actual: 08/06/2022

Sources of funding

- EMA

Study protocol

[Early-COVID-Vaccine-Monitorprotocol_EHRdatav0.2_20210331.pdf](#) (663.74 KB)

[Early-COVID-Vaccine-Monitorprotocol_EHRdatav1.5 CLEAN.pdf](#) (1.36 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Data collection methods:

Combined primary data collection and secondary use of data

Main study objective:

To monitor the use and effects of COVID-19 vaccines

Study Design

Non-interventional study design

Cohort

Other

Non-interventional study design, other

Retrospective, multi-database, dynamic study

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(J07BC20) combinations

combinations

Medical condition to be studied

Coagulopathy

Additional medical condition(s)

Cardiovascular, Immunological

Population studied

Short description of the study population

The study involved participants from 4 European countries, including Italy, the Netherlands, Spain, and the United Kingdom, spanning from January 1st, 2020 to October 31st, 2021. The source population consisted of approximately 36 million individuals, with 7 million in the Netherlands, 8 million in Spain, 3.5 million in Italy, and 16 million in the UK.

Age groups

- Preterm newborn infants (0 - 27 days)
 - Term newborn infants (0 - 27 days)
 - Infants and toddlers (28 days - 23 months)
 - Children (2 to < 12 years)
 - Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Special population of interest

Hepatic impaired

Immunocompromised

Pregnant women

Renal impaired

Estimated number of subjects

5000000

Study design details

Data analysis plan

Risk estimation

Documents

Study publications

Sturkenboom M, Messina D, Paoletti O, de Burgos-Gonzalez A, García-Poza P, Huer...

Sturkenboom M. Cohort monitoring of Adverse Events of Special Interest and COVI...

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Clinical Practice Research Datalink

PHARMO Data Network

BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)

ARS Toscana

Data source(s), other

CPRD, PHARMO Data Network, BIFAP, ARS

Data sources (types)

Administrative healthcare records (e.g., claims)

Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No